duloxetine + escitalopram + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Depression
Conditions
Depression
Trial Timeline
Nov 1, 2003 → May 1, 2005
NCT ID
NCT00073411About duloxetine + escitalopram + placebo
duloxetine + escitalopram + placebo is a phase 3 stage product being developed by Eli Lilly for Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00073411. Target conditions include Depression.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00414323 | Phase 1 | Completed |
| NCT00073411 | Phase 3 | Completed |
Competing Products
20 competing products in Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine and Fluoxetine combination (OFC) + Fluoxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| Quetiapine | Astellas Pharma | Pre-clinical | 23 |
| duloxetine | Eli Lilly | Approved | 85 |
| Duloxetine Hydrochloride | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |
| Duloxetine | Eli Lilly | Approved | 85 |
| Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro) | Eli Lilly | Approved | 85 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |
| duloxetine + fluoxetine + citalopram + paroxetine + sertraline | Eli Lilly | Approved | 85 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Fluoxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| duloxetine + duloxetine | Eli Lilly | Pre-clinical | 23 |
| olanzapine + ziprasidone | Eli Lilly | Approved | 85 |
| Olanzapine Fluoxetine Combination (OFC) + Placebo | Eli Lilly | Approved | 85 |
| Drug treatment with Cymbalta | Eli Lilly | Approved | 85 |
| Duloxetine | Eli Lilly | Approved | 85 |
| Duloxetine | Eli Lilly | Approved | 85 |